Pulsed Field Ablation to Treat Atrial Fibrillation: Autonomic Nervous System Effects
- PMID: 36752473
- DOI: 10.1016/j.jacep.2022.10.028
Pulsed Field Ablation to Treat Atrial Fibrillation: Autonomic Nervous System Effects
Abstract
Background: During atrial fibrillation ablations using thermal energy, the treatment effect is attributed to not just pulmonary vein isolation (PVI), but also to modulation of the autonomic nervous system by ablation of cardiac ganglionated plexi (GP).
Objectives: This study sought to assess the impact of pulsed field ablation (PFA) on the GP in patients undergoing PVI.
Methods: In the retrospective phase, heart rate was assessed pre- versus post-PVI using PFA, cryoballoon ablation, or radiofrequency ablation. In the prospective phase, a pentaspline PFA catheter was used in a protocol: 1) pre-PFA, high-frequency stimulation (HFS) identified GP sites by vagal effects; 2) PVI was performed assessing for repetitive vagal effects over each set of PF applications; 3) mapping defined PVI extent to identify those GP in the ablation zone; and 4) repeat HFS at GP sites to assess for persistence of vagal effects.
Results: Between baseline and 3 months, heart rates in the retrospective radiofrequency ablation (n = 40), cryoballoon (n = 40), and PFA (n = 40) cohorts increased by 8.9 ± 11.4, 11.1 ± 9.4, and -0.1 ± 9.2 beats/min, respectively (P= 0.01 PFA vs radiofrequency ablation; P= 0.01 PFA vs cryoballoon ablation). In the prospective phase, pre-PFA HFS in 20 additional patients identified 65 GP sites. During PFA, vagal effects were noted in 45% of first PF applications, persisting through all applications in 83%. HFS post-PFA reproduced vagal effects in 29 of 38 sites (76%) in low-voltage tissue.
Conclusions: PFA has minimal effect on GP. Unlike with thermal ablation, the mechanism by which PFA treats atrial fibrillation is mediated solely by durable PVI.
Keywords: atrial fibrillation; cardiac autonomic nervous system; pulsed field ablation.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Funding Support and Author Disclosures Dr Neuzil has received grant support from, and has served as a consultant to Farapulse Inc. Dr Dukkipati has equity in Farapulse Inc. Dr Reddy has served as a consultant to and owns equity in Farapulse Inc, Ableton, Acutus Medical, Affera, Apama Medical–Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNOVA EP Technology, East End Medical, EPD-Philips, EP Frontiers, EPIX Therapeutics, EpiEP, Eximo, HRT, Intershunt, Javelin, Kardium, Keystone heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Weber, Oracle Health, Restore Medical, Sirona Medical, and Valcare, is a consultant to Abbott, AtiAN, Biosense-Webster, BioTel Heart, Biotronik, Boston Scientific, Cardiofocus, Cardionomic, CoreMap, EBR, Fire1, W. L. Gore and Associates, Impulse Dynamics, Medtronic, Philips, and Pulse Biosciences, and holds equity in Manual Surgical Sciences, Newpace, Surecor, and Vizaramed. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment in
-
Impact of Pulsed Field Ablation on Autonomic Nervous System: Unwinding Ariadne's Thread.JACC Clin Electrophysiol. 2023 Apr;9(4):494-496. doi: 10.1016/j.jacep.2022.11.024. Epub 2023 Mar 22. JACC Clin Electrophysiol. 2023. PMID: 37100531 No abstract available.
-
Evaluating autonomic outcomes after pulmonary vein isolation: The differential effects of pulsed-field and radiofrequency energy.Heart Rhythm. 2024 Aug;21(8):1250-1252. doi: 10.1016/j.hrthm.2024.04.075. Epub 2024 Apr 23. Heart Rhythm. 2024. PMID: 38663788 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical